On September 9, METIS TECHBIO-P rose 5.46% in regular trading, trading at HK$18.53/share, with turnover of HK$261 million. The stock has accumulated gains of over 30% since its formal inclusion in the Stock Connect program on September 7, continuing to lead the AI pharmaceutical sector.

The rally is driven by multiple catalysts converging in recent sessions. The Shanghai Stock Exchange confirmed METIS TECHBIO-P was officially added to the Stock Connect eligible securities list effective September 7, unlocking direct access for mainland investors via southbound trading channels. Additionally, the company signed a long-term strategic cooperation agreement with Green Leaf Pharmaceutical, becoming its first strategic partner in AI-powered drug delivery.

Fundamentally, the company reported H1 revenue of RMB 154 million, a year-over-year surge of 13,399%, exceeding full-year prior-year revenue by 47%. Adjusted net losses narrowed 56.4% to RMB 51.1 million. The company also secured a landmark global exclusive licensing deal for its MTS-128 project worth up to US$1.6 billion in milestone payments, setting a new record for pre-clinical TCE transactions in China.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)